Health Care [ 3/12 ] | Biotechnology [ 13/73 ]
NASDAQ | Common Stock
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States.
Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc).
Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 25 | -0.01 Increased by +97.46% | -0.01 Increased by +30.00% |
| Mar 5, 25 | -0.01 Increased by +96.99% | -0.01 Increased by +20.00% |
| Nov 14, 24 | -0.01 Increased by +50.00% | -0.01 |
| Aug 21, 24 | -0.26 Decreased by -622.22% | -0.01 Decreased by -2.50 K% |
| May 9, 24 | -0.28 Increased by +65.59% | -0.03 Decreased by -817.67% |
| Mar 7, 24 | -0.27 Decreased by -563.50% | -0.02 Decreased by -1.23 K% |
| Nov 9, 23 | -0.02 Increased by +50.00% | -0.02 |
| Aug 14, 23 | -0.04 Increased by +93.33% | -0.03 Decreased by -20.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -3.32 M Increased by +15.03% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -2.96 M Increased by +14.22% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -3.48 M Increased by +14.38% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -3.63 M Increased by +54.44% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -3.91 M Increased by +55.32% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -3.45 M Increased by +58.24% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -4.07 M Increased by +51.09% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -7.97 M Decreased by -28.76% | Decreased by N/A% Decreased by N/A% |